Breaking News Instant updates and real-time market news.

ASLN

Aslan Pharmaceuticals

$3.20

(0.00%)

05:56
05/31/19
05/31
05:56
05/31/19
05:56

Aslan Pharmaceuticals acquires full commercial rights for ASLAN004 from CSL

Aslan Pharmaceuticals announced that it has amended its license agreement with CSL so that ASLAN has full global rights to develop, manufacture and commercialise ASLAN004 in all indications. The amended agreement replaces the licensing agreement ASLAN and CSL signed in May 2014. Under the terms of the amended agreement, ASLAN will make a first payment of US$30 million to CSL upon commencement of a phase 3 study of ASLAN004. CSL is also eligible to receive up to $95 million of regulatory milestones, $655 million of sales milestones and tiered royalties on net sales between mid-single digits and 10%. Under the terms of the original agreement, ASLAN was responsible for the development of ASLAN004 through to proof-of-concept and the identification of a partner to complete phase 3 development and commercialisation. CSL was eligible to receive between 40% and 50% of all ASLAN004 revenues, including proceeds from out-licensing agreements.

ASLN Aslan Pharmaceuticals
$3.20

(0.00%)

01/14/19
HCWC
01/14/19
NO CHANGE
Target $8.5
HCWC
Buy
Aslan Pharmaceuticals price target lowered to $8.50 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Aslan Pharmaceuticals to $8.50 after varlitinib data in first-line gastric cancer didn't show statistical significance. The analyst, however, reiterates a Buy rating on the shares.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $7
PIPR
Overweight
Aslan achieved 'impressive' overall response rate in BTC, says Piper Jaffray
Aslan Pharmaceuticals' varlitinib added to gemcitabine and cisplatine achieved an "impressive" overall response rate of 43.8% and disease control rate of 93.8% in the Phase Ib/II study in first-line biliary tract cancer, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Varlitinib was also well tolerated with the most common adverse events decreases in platelet and neutrophil counts, adds the analyst. The data presented last night increase his confidence in the fully-enrolled Phase III TreeTopp trial of varlitinib in second line biliary tract cancer with top-line data in the second half of 2019. He reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.
01/30/19
PIPR
01/30/19
NO CHANGE
Target $7
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Aslan after restructuring news
After Aslan Pharmaceuticals announced it is conducting a corporate restructuring that will cut headcount by 30% and operating costs by 50%, Piper Jaffray analyst Edward Tenthoff noted the restructuring does not impact development of wholly-owned varlitinib in biliary tract cancer, ASLAN003 in acute myeloid leukemia and ASLAN004 in atopic dermatitis. Tenthoff, who said the primary driver for varlitinib remains Phase 3 TreeTopp trial data in the second half of 2019, reiterates an Overweight rating and $7 price target on Aslan shares.
04/01/19
PIPR
04/01/19
NO CHANGE
Target $7
PIPR
Overweight
Aslan data show comparable activity to Dupixent, says Piper Jaffray
Aslan Pharmaceuticals reported preliminary Phase I single-ascending dose data on intravenous ASLAN004 demonstrating the IL13 receptor antibody to be safe and well tolerated in healthy volunteers with no discontinuations due to adverse events, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. ASLAN004 caused complete inhibition of phosphorylation of STAT6 within one hour lasting for greater than 29 days, adds the analyst. He believes these results present the opportunity for once-monthly dosing of ASLAN004 with comparable activity to Regeneron's (REGN) Dupixent. Tenthoff reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.

TODAY'S FREE FLY STORIES

VBTX

Veritex

$25.67

-0.44 (-1.69%)

17:17
07/22/19
07/22
17:17
07/22/19
17:17
Earnings
Veritex reports Q2 EPS 59c, consensus 62c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

WM

Waste Management

$117.15

0.39 (0.33%)

17:12
07/22/19
07/22
17:12
07/22/19
17:12
Initiation
Waste Management initiated  »

Waste Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

IBTX

Independent Bank

$55.08

-1.08 (-1.92%)

17:05
07/22/19
07/22
17:05
07/22/19
17:05
Earnings
Independent Bank reports Q2 adjusted EPS $1.22, consensus $1.27 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

RNST

Renasant

$34.10

-0.49 (-1.42%)

17:04
07/22/19
07/22
17:04
07/22/19
17:04
Earnings
Renasant reports Q2 EPS 80c with items, consensus 81c »

Reports Q2 net loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

17:03
07/22/19
07/22
17:03
07/22/19
17:03
Hot Stocks
Steel Dynamics announces planned new flat roll steel mill site selection »

Steel Dynamics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Brown & Brown reports Q2 organic revenue up 3.9% »

Reports Q2 EBITDA margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

HAE

Haemonetics

$122.44

0.35 (0.29%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Haemonetics updates financial reporting segments »

Haemonetics Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 05

    Sep

  • 09

    Sep

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:01
07/22/19
07/22
17:01
07/22/19
17:01
Earnings
Brown & Brown reports Q2 adjusted EPS 32c, consensus 28c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

DLX

Deluxe

$41.95

0.41 (0.99%)

17:00
07/22/19
07/22
17:00
07/22/19
17:00
Hot Stocks
Deluxe names Chris Thomas chief revenue officer »

Deluxe Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 19

    Sep

GE

General Electric

$10.22

0.18 (1.79%)

, AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

16:57
07/22/19
07/22
16:57
07/22/19
16:57
Hot Stocks
Avalon GloboCare and GE Healthcare announce strategic partnership »

Avalon GloboCare (AVCO)…

GE

General Electric

$10.22

0.18 (1.79%)

AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 09

    Sep

  • 09

    Sep

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

16:55
07/22/19
07/22
16:55
07/22/19
16:55
Hot Stocks
Breaking Hot Stocks news story on Viveve 

Viveve trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFF

Village Farms

$10.69

0.48 (4.70%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Initiation
Village Farms initiated at Craig-Hallum »

Village Farms initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$75.72

0.995 (1.33%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Hot Stocks
Best Buy beneficial owner Richard Schulze sells $32.4M in company shares »

Best Buy beneficial owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

ORGO

Organogenesis

$5.85

-0.27 (-4.41%)

16:50
07/22/19
07/22
16:50
07/22/19
16:50
Syndicate
Organogenesis commences exchange offer »

Organogenesis Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

WD

Walker & Dunlop

$55.46

-0.39 (-0.70%)

16:49
07/22/19
07/22
16:49
07/22/19
16:49
Hot Stocks
Walker & Dunlop appoints Chief Production Officer to Lead FHA finance team »

Walker & Dunlop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 15

    Aug

EQBK

Equity Bancshares

$24.43

-0.19 (-0.77%)

16:49
07/22/19
07/22
16:49
07/22/19
16:49
Earnings
Equity Bancshares reports Q2 EPS 58c, consensus 60c »

The net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Sep

RPAY

Repay Holdings

$11.51

-0.26 (-2.21%)

16:47
07/22/19
07/22
16:47
07/22/19
16:47
Hot Stocks
Monroe Capital reports 6.5% passive stake in Repay Holdings »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

TRWH

Twin River Worldwide

$28.10

0.1 (0.36%)

16:45
07/22/19
07/22
16:45
07/22/19
16:45
Hot Stocks
Twin River Worldwide extends tender offer expiration time to July 26 »

Twin River Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRWH

Twin River Worldwide

$28.10

0.1 (0.36%)

16:44
07/22/19
07/22
16:44
07/22/19
16:44
Earnings
Twin River Worldwide reports preliminary Q2 revenue $146.5M-$148.5M »

Consensus $161.33M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$137.84

0.55 (0.40%)

, MU

Micron

$47.21

1.7 (3.74%)

16:43
07/22/19
07/22
16:43
07/22/19
16:43
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks rose as earnings…

EFX

Equifax

$137.84

0.55 (0.40%)

MU

Micron

$47.21

1.7 (3.74%)

MTN

Vail Resorts

$235.48

9.665 (4.28%)

SKIS

Peak Resorts

$10.85

5.71 (111.09%)

FB

Facebook

$202.32

3.94 (1.99%)

INTC

Intel

$51.36

1.1 (2.19%)

AVGO

Broadcom

$296.11

6.06 (2.09%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

BX

Blackstone

$47.81

2.18 (4.78%)

CQP

Cheniere Energy Partners

$43.96

0.835 (1.94%)

BYND

Beyond Meat

$193.91

17.26 (9.77%)

HAL

Halliburton

$23.76

2.02 (9.29%)

PAYS

Paysign

$13.68

-3.81 (-21.78%)

CADE

Cadence Bancorp

$15.86

-3.75 (-19.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

  • 12

    Aug

  • 26

    Aug

  • 27

    Aug

  • 23

    Sep

  • 26

    Sep

  • 27

    Oct

  • 13

    Nov

ACAD

Acadia

$25.97

0.28 (1.09%)

16:36
07/22/19
07/22
16:36
07/22/19
16:36
Hot Stocks
Breaking Hot Stocks news story on Acadia »

Acadia down over 16% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 20

    Aug

ACAD

Acadia

$25.97

0.28 (1.09%)

16:35
07/22/19
07/22
16:35
07/22/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Acadia 

Acadia trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 20

    Aug

FULC

Fulcrum Therapeutics

$12.84

0.35 (2.80%)

16:34
07/22/19
07/22
16:34
07/22/19
16:34
Hot Stocks
Fulcrum Therapeutics chairman Mark Levin buys $1.3M in company shares »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$105.66

-1.35 (-1.26%)

16:34
07/22/19
07/22
16:34
07/22/19
16:34
Earnings
Celanese still sees 'path to' FY19 EPS of $10.50, consensus $10.20 »

CEO Lori Ryerkerk says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FTI

TechnipFMC

$25.61

0.5 (1.99%)

16:33
07/22/19
07/22
16:33
07/22/19
16:33
Hot Stocks
TechnipFMC awarded iEPCI contract from Neptune Energy for Seagull project »

TechnipFMC has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.